NASDAQ:RENB

Renovaro (RENB) Stock Price, News & Analysis

$0.97
+0.05 (+5.75%)
(As of 05/17/2024 08:54 PM ET)
Today's Range
$0.90
$1.00
50-Day Range
$0.92
$3.23
52-Week Range
$0.39
$5.25
Volume
153,400 shs
Average Volume
293,828 shs
Market Capitalization
$143.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RENB stock logo

About Renovaro Stock (NASDAQ:RENB)

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

RENB Stock Price History

RENB Stock News Headlines

Renovaro Inc. (RENB)
Renovaro: Fiscal Q3 Earnings Snapshot
Renovaro Shareholder Notice
Renovaro Shareholder Alert
RENB Apr 2024 2.500 call
Renovaro Ongoing Investor Alert
Renovaro Biosciences Inc.: Statement of Renovaro Inc
See More Headlines
Receive RENB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
5/19/2024
Fiscal Year End
6/30/2024
Next Earnings (Estimated)
10/07/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RENB
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-39,680,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.14 per share

Miscellaneous

Free Float
115,467,000
Market Cap
$143.08 million
Optionable
Optionable
Beta
0.44
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Hon. Mark R. Dybul M.D. (Age 60)
    CEO, Director & Member of HBV Scientific Advisory Board
    Comp: $764.58k
  • Dr. Francois Binette M.Sc. (Age 60)
    Ph.D., COO and Executive VP for Research & Development
    Comp: $504.38k
  • Dr. Serhat Gümrükcü
    Co-Founder & Inventor
  • Mr. Simon Tarsh (Age 62)
    Interim Chief Financial Officer
  • Mr. Greg Duczynski Ph.D.
    Senior Vice President for Clinical Operations

RENB Stock Analysis - Frequently Asked Questions

How have RENB shares performed in 2024?

Renovaro's stock was trading at $3.17 at the beginning of 2024. Since then, RENB shares have decreased by 69.4% and is now trading at $0.97.
View the best growth stocks for 2024 here
.

When is Renovaro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 7th 2024.
View our RENB earnings forecast
.

What ETF holds Renovaro's stock?

Amplify Treatments, Testing and Advancements ETF holds 33,976 shares of RENB stock, representing 0.50% of its portfolio.

Who are Renovaro's major shareholders?

Renovaro's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.73%), Tidal Investments LLC (0.03%) and SG Americas Securities LLC (0.01%).

How do I buy shares of Renovaro?

Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RENB) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners